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Erythropoietin (EPO) exerts potent neuroprotective, neuroregenerative and 
procognitive functions. However, unequivocal demonstration of erythropoietin 
receptor (EPOR) expression in brain cells has remained difficult since previously 
available anti-EPOR antibodies (EPOR-AB) were unspecific. We report here a new, 
highly specific, polyclonal rabbit EPOR-AB directed against different epitopes in the 
cytoplasmic tail of human and murine EPOR and its characterization by mass 
spectrometric analysis of immunoprecipitated endogenous EPOR, Western blotting, 
immunostaining, and flow cytometry. Among others, we applied genetic strategies 
including overexpression, Lentivirus-mediated conditional knockout of EpoR, and 
tagged proteins, both on cultured cells and tissue sections, as well as intracortical 
implantation of EPOR-transduced cells to verify specificity. We show examples of 
EPOR expression in neurons, oligodendroglia, astrocytes, and microglia. Employing 
this new EPOR-AB with double-labelling strategies, we demonstrate membrane 
expression of EPOR as well as its localization in intracellular compartments such as 
the Golgi apparatus. Moreover, we show injury-induced expression of EPOR: In 
mice, a stereotactically applied stab wound to the motor cortex leads to distinct EpoR 
expression by reactive GFAP-expressing cells in the lesion vicinity. In a patient 
suffering from epilepsy, neurons and oligodendrocytes of the hippocampus strongly 
express EPOR. To conclude, this new analytical tool will allow neuroscientists to 
pinpoint EPOR expression in cells of the nervous system and to better understand its 
role in healthy conditions, including brain development, as well as under pathological 
























The growth factor erythropoietin (EPO) was named based on its first discovered 
effects on cells of the hematopoietic system. For >20 years it has been shown to act 
on other tissues, including the brain, e.g. (1-5). Its remarkable neuroprotective, 
neuroregenerative and procognitive effects make EPO an attractive candidate for 
treating human brain disease, e.g. (6-7), and an important target of neuroscience 
research. In 1989, the EPO receptor (EpoR) has first been cloned in mouse (8), soon 
followed by cloning and characterization of the human EPOR gene (9-10). A single 
EPO molecule binds to 2 specific cytokine type1 transmembrane receptor molecules, 
each with a calculated molecular mass of 59kDa, that together form the classical 
homodimeric EPOR (2, 11). Binding of EPO to its receptor induces a conformational 
change, initiating EPOR-associated JAK2 transphosphorylation and multiple, cell-
type specific, downstream signal transduction cascades. These cascades include 
signal transducers and activators of transcription (STATs), phosphatidylinositol-3 
kinase (PI3K)/AKT, RAS/extracellular signal-regulated kinase (ERK1/2), nuclear 
factor kappa B (NF-kappa B). Activation of these signaling cascades leads to further 
activation of anti-apoptotic factors and pathways, stimulation of cell differentiation, 
including induction of cellular shape-change and growth, or modulation of plasticity, 
in a cell-type and stimulation-dependent manner (5, 12-13).  
 
Antibodies against EPOR (EPOR-AB) have been widely used to characterize EPOR 
expression and localization, but cell surface EPOR expression is low, even in 
stimulated states, and most importantly, all commercially available EPOR-AB have 
been hampered by non-specific cross-reactivities, questioning the exclusively hereon 
based literature. This in turn raised discussions within the scientific community, 
questioning the expression of EPOR in extra-hematopoietic tissues (14-16). These 
discussions were likely nurtured by conflicts of interest, trying to ‘restrict’ the effects 
of EPO, a commercially for the anemia market highly attractive compound, to 
hematopoiesis. Nevertheless, they made it very obvious that the existing EPOR-AB 
were essentially unreliable, and that the production and thorough characterization of 




















Independent of work based on EPOR-AB, genetically altered mice helped to 
demonstrate that EPOR signalling is necessary for normal brain development (19) 
and that it has a distinct function in neurogenesis (20). In addition, EPO and EPOR 
mRNA are expressed in brain tissue (21), and specific binding sites for EPO in brain 
have been demonstrated in mouse and human by means of radiolabelled EPO (22-
23). In cell culture, mRNA expression combined with functional assays, e.g. altered 
phosphorylation of second messenger pathways induced by EPO in microglia, served 
to prove specific EPOR expression in the absence of reliable EPOR-AB (24). 
 
The fact that cellular EPOR protein expression has been difficult to assess, strongly 
limited the in-depth investigation of the EPO/EPOR system. Particularly in the human 
brain, the study of its (patho-) physiological role has been highly constrained since 
additional means of verification as used in experimental animals and cell cultures are 
naturally excluded. Recognizing this critical issue in EPO/EPOR research, we aimed 
at generating reliable EPOR-AB. We present here the comprehensive 
characterization of a novel, highly specific EPOR-AB, using an array of state-of-the-
art technologies. This new AB tool may help overcome the described obstacles and 





MATERIALS AND METHODS 
 
Generation of EPOR-AB 
Polyclonal AB 
Two rabbits were immunized with a purified recombinant protein corresponding to 
amino acids (AA) 273-508 (intracellular C-terminus) of the unprocessed human 
EPOR. The coding sequence was generated by gene synthesis (Geneart, 
Regensburg, Germany) and ligated via EcoRI and HindIII into the bacterial 
expression vector pASK-IBA37+ (IBA-Lifescience, Göttingen, Germany). The 
recombinant His-Tag fusion protein was expressed and purified by Ni-NTA affinity 
chromatography according to the manufacturer’s manual. Crude antiserum SA7378 


















Healthcare, Freiburg, Germany). The AB is referred to as ctEPOR-AB in this 
manuscript. 
Monoclonal AB 
AB producing hybridomas were generated by Synaptic Systems (Göttingen; see also 
http://www.sysy.com/mabservice.html) as follows: Three 8–10 weeks old BALB/c 
female mice were subcutaneously immunized with a synthetic peptide corresponding 
to AA 25-39 (extracellular N-terminus) of unprocessed human EPOR precursor 
coupled to KLH via a C-terminal cysteine over a period of 75 days. Cells from the 
knee lymph nodes were fused with the mouse myeloma cell line P3X63Ag8.653 
(ATCC CRL-1580). Resulting hybridomas were screened by direct ELISA against the 
immunogen and immunofluorescence on 3T3 NIH fibroblasts overexpressing full-
length human EPOR. Clone 45A3, used in this study, was re-cloned two times by 
limiting dilution and the immunoglobulin subclass was determined (IgG2b). The AB is 
referred to as ntEPOR-AB in this manuscript. 
 
Cell culture  
Cell lines 
The following human cell lines were used: [1] The EPO-dependent 
megakaryoblastic leukaemia UT-7 cell line (kind gift from Drorit Neumann, Tel Aviv 
University, Israel). This cell line was cultured in IMDM with 1% GlutaMAX supplement 
(Invitrogen, Darmstadt, Germany), 10% FBS, 100U/mL penicillin and 100µg/mL 
streptomycin (all Life Technologies GmbH, Darmstadt, Germany) and 2IU/mL EPO 
(NeoRecormon, Roche, Welwyn Garden City); [2] The erythroleukaemia cell line 
OCIM-1 (DSMZ  GmbH, Braunschweig, Germany) was cultured in IMDM with 1% 
GlutaMAX supplement, 10% FBS and 100U/mL penicillin and 100µg/mL 
streptomycin (all Life Technologies GmbH); [3] The mouse microglia cell line EOC-
20 (ATTC LGC Standards, Wesel, Germany) was cultured in DMEM with 1mM 
sodium pyruvate, 0.15%sodium bicarbonate, 10% FBS, 100U/mL penicillin,100µg/mL 
streptomycin (all Life Technologies GmbH) and 0.01 µg/mL murine M-CSF (PAN-
Biotech, Aidenbach, Germany); [4] HEK293 FT cells (Sigma-Aldrich, Taufkirchen, 
Germany) were cultured in DMEM with 5 % FBS and 100U/mL penicillin and 



















Human IPS cells 
Human material was used in accordance with ethical guidelines and the Helsinki 
Declaration. Subjects gave informed consent regarding generation and use of IPS 
cells or scientific investigation of brain samples. Human fibroblasts were 
reprogrammed using a non-integrative RNA-based virus to induce the expression of 
4 reprogramming factors: OCT4, SOX2, KLF4 and c-MYC (CytoTune®-iPS 2.0 
Sendai Reprogramming Kit, Life Technologies GmbH). After transduction, IPS cells 
(clones isAu1-3; isAu3-2) were adapted to a feeder-free culture system (Matrigel® 
matrix, Corning, Wiesbaden, Germany) and cultured in TeSR™-E8™ medium (Stem 
Cell TechnologiesTM, Cologne, Germany). 
 
Primary mouse cell culture 
The preparation and culture conditions of primary mouse oligodendrocytes and 
microglia are described in detail elsewhere (24-25). In brief, oligodendrocytes were 
prepared from the forebrains of newborn P1-2 NMRI mice. After differentiation, 
oligodendrocyte precursors were shaken off from a bottom layer of astrocytes and 
seeded in Super-Sato medium (DMEM with high glucose supplemented with B-27 
supplement, 2mM GlutaMAX, 1mM sodium pyruvate, 1% horse serum (HS), 50U/mL 
penicillin and 50µg/mL streptomycin, all from Life Technologies GmbH) and 0.5mM 
triiodothyronine, and 0.52mM L-thyroxine both Merck, Darmstadt, Germany). For 
primary microglia, newborn C57BL6 mice (P0-P1) were used. The cell suspension 
derived from their forebrains was seeded in high glucose DMEM medium with 10% 
HS, 1% GlutaMAX supplement, 50U/mL penicillin and 50µg/ml streptomycin (all from 
Life Technologies GmbH). Half of the microglia-conditioned medium was exchanged 
by fresh medium 3-4 days later, and at day 7, the medium was partially replaced by 
L929-conditioned medium. Primary microglia were detached by shaking of flasks and 
seeded in serum-free microglial growth medium (high glucose DMEM with 1mM 
sodium pyruvate, 1.5g/L sodium bicarbonate, 100U/mL penicillin and 100µg/mL 
streptomycin, all from Life Technologies GmbH).  
 
Lentiviral transduction of primary cells 
EpoR conditional mouse mutants with floxed exons 3-6  were generated on the 


















(EPD0316_5_A03) from the International Mouse Phenotyping Consortium. Details 
will be published elsewhere and are available upon request. Primary mouse 
astrocytes prepared from P0-2 forebrains of EpoR-fl/fl mice were used. The 
preparation and culture conditions of these cells are described in detail elsewhere 
(26). The cells were infected with lentiviruses at day1 in vitro. The viral constructs 
contained either a cassette for GFP only (control) or a cassette for GFP and Cre-
recombinase. Protein was extracted on day10 in vitro.  
 
EOC-20 cell transduction 
For viral transduction 100,000 EOC-20 cells were seeded in 12-well plates overnight. 
The next day, the medium was partially exchanged by DMEM (Life Technologies 
GmbH) containing viral supernatant and 8µg/mL polybrene (Sigma-Aldrich). The 
ecotropic virus particles used were derived from a pMOWS vector encoding N-
terminally HA-tagged full-length human EPOR and puromycin resistant cassettes 
(kind gift from Ursula Klingmüller, DKFZ Heidelberg, Germany) (27). Next, the 12-well 
plates were centrifuged for 3h at 1640rpm at room temperature (RT). The medium 
was exchanged again to DMEM with 1mM sodium pyruvate, 0.15%sodium 
bicarbonate, 10% FBS, 100U/mL penicillin, 100µg/mL streptomycin (all Life 
Technologies GmbH) and 0.01 µg/mL murine M-CSF (PAN-Biotech). The medium 
was supplemented 1 day later with 6µg/mL puromycin (Sigma-Aldrich) for selection 
of successfully transduced EOC-20 cells. After successful transduction, cells were 
constantly cultured in the presence of 6µg/mL puromycin.  
 
HEK293 FT cell transfection 
HEK293 FT cells were transfected with Lipofectamine®2000 reagent (Life 
Technologies GmbH) according to the manufacturer’s instructions. The pEuExpress-
hEPOR vector (Synaptic Systems, Göttingen, Germany) was used to transfect the 
cells with full-length human EPOR (~60 kDa), full-length murine EpoR (~60 kDa), an 
N-terminally HA-tagged and C-terminally truncated human EPOR (lacks the 
intracellular domain, ~40 kDa) and an anchored human EPOR (lacks the N-terminus 





















STAT5 phosphorylation assay 
This assay is described in detail elsewhere (17). In brief, UT-7 or OCIM-1 cells were 
serum- and EPO-deprived overnight (1% FBS in IMDM, both Life Technologies 
GmbH). On the next day, they were incubated with different concentrations of 
recombinant human EPO (rhEPO, NeoRecormon, Roche) or control solution for 
15min, followed by protein extraction for Western blotting. Immunodetection was 
done with anti-phosphorylated STAT5 (1:500, Cell Signaling, Danvers, MA, USA) and 
GAPDH (1:5000, Enzo Life Sciences, Farmingdale, NY, USA); 20µg of protein was 
loaded for SDS-PAGE. 
 
MAPK phosphorylation assay 
Transduced EOC-20 cells were kept in serum free DMEM (Life Technologies GmbH) 
overnight. Then, cells were incubated with different concentrations of rhEPO 
(NeoRecormon, Roche) or the respective control solution for 10 min, followed by 
protein extraction for Western blotting. Immunodetection was done with anti-
phosphorylated MAPK (1:1000), anti-MAPK (1:5000) and anti-alpha-tubulin (1:5000, 
all from Sigma-Aldrich); 15µg of protein was loaded for SDS-PAGE. 
 
Animal experiments 
All experiments were approved by and conducted in accordance with the regulations 
of the local Animal Care and Use Committee (Niedersächsisches Landesamt für 
Verbraucherschutz und Lebensmittelsicherheit – LAVES). 
 
Stereotactic cell implantation 
Male C57BL/6N mice, 8 weeks old, were used. Animals were injected 
intraperitoneally (i.p.) with carprofen (5mg/kg Rimadyl®, Pfizer, Berlin, Germany) 2h 
before surgery. Under anaesthesia (0.276mg/g Tribromoethanol, Sigma-Aldrich, St. 
Luis, Minnesota, USA), mice were positioned in a stereotactic frame and a small, 
midline scalp incision was made. A hole was drilled over the left cranial hemisphere 
at a position 1.5mm anterior and 1.0mm lateral to the bregma. Using a sterile 10mL 
Hamilton syringe with a 26-gauge needle, 15,000 transduced EOC-20 cells 
(description see above) or medium only (DMEM without phenol-red, Life 


















motor cortex. After implantation, the needle was left in place for 2min, then slowly 
withdrawn from the brain and the skin incision closed with sterile suture. Directly after 
the skin incision was closed, the animals received carprofen i.p. for pain treatment 
which was repeated every 6-8h (5mg/kg Rimadyl®, Pfizer). At 24h after surgery, 
animals were anesthetized i.p. (0.276mg/g Tribromoethanol; Sigma-Aldrich) and 
perfused transcardially with 0.9% saline followed by 4% formaldehyde in PBS.  
 
Labelling of oligodendrocyte precursor cells in vivo 
For induction of CreERT2-activity in NG2-Cre-ERT2:R26R-td-tomato-mEGFP mice 
(28-29), 100mg/kg tamoxifen (dissolved in corn oil; Sigma-Aldrich, Taufkirchen, 
Germany) was injected i.p. at postnatal days 26 and 27. At 72h later, animals were 
anesthetized i.p. (0.276mg/g Tribromoethanol, Sigma-Aldrich) and perfused 
transcardially with 0.9% saline followed by 4% formaldehyde in PBS. 
   
Detection of EPOR 
Immunoprecipitation 
UT-7 protein lysates were obtained using an immunoprecipitation (IP) buffer (150mM 
NaCl, 20mM Tris, 1mM EDTA, 10% glycerol, pH=7.4)  containing 1% Triton X-100. 
Before IP, lysates were diluted 1:1 with IP buffer to obtain 0.5% Triton X-100. For the 
EPOR IP, protein-G sepharose beads were covalently linked to ctEPOR-AB 
(Synaptic Systems) with 40mmol/L dimethyl-pimelimidate (Sigma-Aldrich). Bead 
slurry (200µL; Thermo Scientific, Waltham, MA, USA) was cross-linked with 400µg 
ctEPOR-AB or 400µg of the IgG fraction from the same rabbit before immunization. 
For EPOR IP from UT-7 protein lysates, 9µg of ctEPOR-AB coupled to protein-G 
sepharose per 1mg protein lysate were incubated for 2h at 4°C. Afterwards, beads 
were centrifuged and washed. For immunoblot analysis, EPOR was eluted from the 
beads by repeated boiling in Laemmli buffer at 95°C. For mass spectrometric protein 
identification, EPOR was eluted as before but with a non-reducing SDS-buffer 
(without β-mercaptoethanol) to prevent masking of the EPOR by excess AB heavy 
chains in the subsequent gel electrophoresis. To increase the efficiency of EPOR 
capture from UT-7 protein lysates, 2 consecutive IP with fresh beads were performed 
in a way that the flow-through of the first IP was used as input for the second. Eluted 


















solubilized in reducing sample buffer and pooled prior to electrophoresis. As starting 
material for mass spectrometry 4mg protein lysate from UT-7 cells was used. 
 
SDS-PAGE and Western blots 
SDS-PAGE was performed with self-made 10% SDS-polyacrylamide gels. As protein 
ladder we used PageRulerTM Plus pre-stained and SeeBlue Plus2 pre-stained in this 
gel system (both Life Technologies GmbH). For all Western blotting, the following 
protein amounts were loaded:  [1] 15 µg for lysates derived from cell lines; [2] 20 µg 
for lysates derived from primary cultures; [3] 50 µg for lysates derived from tissue. 
Afterwards, proteins were transferred to a nitrocellulose membrane and blocked with 
4% milk powder and 4% HS in Tris buffered saline with 0.05% Tween 20. 
Membranes were incubated with ctEPOR-AB (1:2000, Synaptic Systems) at 4°C 
overnight. For all EPOR immunoblots, membranes were washed, blocked again and 
incubated with donkey anti-rabbit IRDye 800 AB (1:10000, Rockland, Limerick, PA, 
USA) for 1h at RT. Primary mouse AB were detected with donkey anti-mouse IRDye 
800 AB (1:10000, Rockland) for 1h at RT.  After washing, the membranes were 
scanned with Odyssey imager (LI-COR Biosciences, Lincoln, NE, USA) and analyzed 
with the Image Studio software. Gel electrophoresis for mass spectrometric protein 
identification were performed in parallel on precast NuPAGE 4-12% Bis-Tris gradient 
gels using a 3-(N-morpholino)propanesulfonic acid (MOPS) buffer system according 
to the manufacturer (Invitrogen). As protein ladder we used SeeBlue Plus2 pre-
stained in this gel system (Life Technologies GmbH). Proteins were either visualized 
by colloidal Coomassie staining (gel 1) or transferred on PVDF membranes and 
immunodetected as described above (gel 2). 
 
Protein identification 
Gel regions of interest were identified by overlaying images from colloidal Coomassie 
staining and immunodetection in the Delta 2D image analysis software (Decodon, 
Greifswald, Germany). Gel bands were excised manually and subjected to 
automated in-gel digestion with trypsin as described previously (31). Tryptic peptides 
were dried down in a vacuum centrifuge, re-dissolved 0.1 % trifluoro- acetic acid and 
spiked with 2.5fmol/μL of yeast enolase1 tryptic digest standard (Waters Corporation, 


















separation of tryptic peptides was performed with a nanoAcquity UPLC system 
equipped with a Symmetry C18 5μm, 180μm × 20mm trap column and a BEH C18 
1.7μm, 75μm × 100mm analytical column (Waters Corporation). Peptides were 
separated over 60min at a flow rate of 300nL/min with a linear gradient of 1-45 % 
mobile phase B (acetonitrile containing 0.1 % formic acid) while mobile phase A was 
water containing 0.1 % formic acid. Mass spectrometric analysis of tryptic peptides 
was performed using a Synapt G2-S quadrupole time-of-flight mass spectrometer 
equipped with ion mobility option (Waters Corporation). Positive ions in the mass 
range m/z 50 to 2000 were acquired with a typical resolution of at least 20,000 
FWHM (full width at half maximum) and data were lock mass corrected post-
acquisition. With the aim of increasing the sequence coverage of the identified 
proteins, analyses were performed in the ion mobility-enhanced data-independent 
acquisition mode (33-34) with drift time-specific collision energies (35). For protein 
identification, continuum LC-MS data were processed and searched using Waters 
ProteinLynx Global Server version 3.0.2 (36). A custom database was compiled by 
adding the sequence information for yeast enolase 1 and porcine trypsin to the 
UniProtKB/Swiss-Prot human proteome (UniProtKB release 2015_06, 20,206 entries) 
and by appending the reversed sequence of each entry to enable the determination 
of false discovery rate (FDR). Precursor and fragment ion mass tolerances were 
automatically determined by PLGS 3.0.2 and were typically below 5ppm for precursor 
ions and below 10ppm (root mean square) for fragment ions. Carbamidomethylation 
of cysteine was specified as fixed and oxidation of methionine as variable 
modification. One missed trypsin cleavage was allowed. The FDR for protein 
identification was set to 1% threshold.  
 
Flow cytometry 
UT-7 cells were fixed with 4% Histofix solution (Carl Roth, Karlsruhe, Germany). For 
EPOR staining, cells were blocked, permeabilized with 5% normal horse serum 
(NHS) and 0.5% Triton X-100, and incubated with ctEPOR-AB (1:500, Synaptic 
Systems) and Hoechst (5µg/mL Invitrogen) or for control only Hoechst for 30min on 
ice. After washing, cell suspensions were incubated with Alexa488 donkey anti-rabbit 
(1:250, Life Technologies GmbH) for 30min on ice, followed by FACS analysis 



















Cells were fixed with 4% formaldehyde in PBS for 20min, permeabilized and blocked 
in 0.2% Triton X-100 with 10% NHS in PBS for 20min. After washing with 1% NHS in 
PBS, cells were incubated overnight at 4°C with the primary AB in 0.2% Triton X-100  
with 1% NHS in PBS. The following primary AB were used:  Rabbit ctEPOR-AB 
(1:1000, Synaptic Systems), mouse ntEPOR-AB (1:1000, Synaptic Systems), mouse 
anti-HA (1:500, Covance Inc., Princeton, USA), mouse anti-GM130 (1:100, BD 
Biosciences, Heidelberg, Germany), rat anti-NG2 (1:250, kind gift from Dr Trotter, 
University of Mainz, Germany), goat anti-human Oct-3/4 (1:40, R&D Systems, 
Minneapolis, MN, USA). After washing, cells were incubated with the following 
secondary AB in 0.2% Triton X-100 with 1% NHS in PBS for 1h at RT: Donkey anti-
rabbit Alexa488 and anti-goat Alexa488, donkey anti-mouse Alexa568, donkey anti-
rabbit Alexa594 (all 1:500, Life Technologies GmbH) and goat anti-rat Alexa488 
(1:250, Jackson ImmunoResearch, West Grove, PA, USA). Primary microglia were 
counterstained with tomato lectin Alexa488 (1:250, Vector Laboratories, Burlingame, 
CA, USA). Cell nuclei were visualized with DAPI dissolved in H20 (0.01µg/mL, 
Sigma-Aldrich). Afterwards, the coverslips were dried and mounted with Aqua-
Poly/Mount (Polysciences, Warrington, PA, USA). All stainings were scanned by 
confocal microscopy (TCS SP5-II, Leica, Wetzlar, Germany). Illustration was done 
using Imaris 7.5.1 (www.bitplane.com). 
 
Immunohistochemistry on frozen mouse sections 
C57BL6/N mice, 5 weeks old, were anesthetized by i.p. injection (0.276mg/g 
Tribromoethanol, Sigma-Aldrich) and perfused transcardially with 0.9% saline 
followed by 4% formaldehyde in PBS. Brains were removed, post-fixed overnight at 
4°C with 4% formaldehyde in PBS and placed in 30% sucrose in PBS for 
cryoprotection and stored at -20˚C. Whole mouse brains were cut into 30µm thick 
coronal sections on a cryostat (Leica). Frozen sections were permeabilized and 
blocked with 0.5% Triton X-100 and 5% NHS in PBS for 1h at RT. Then, sections 
were incubated with the following primary AB in 3% NHS, 0.5% Triton X-100 in PBS 
for 48h at 4°C:  Rabbit ctEPOR-AB (1:200), chicken anti-NeuN (266 006; 1:500), 
guinea pig anti-GFAP (173 004; 1:500, all Synaptic Systems) and mouse anti-APC 


















following secondary AB in 3% NHS, 0.5% Triton X-100 in PBS for 1.5h at RT: 
Donkey anti-rabbit Alexa594, donkey anti-mouse Alexa488 (both 1:500; Life 
Technologies GmbH), donkey anti-chicken (1:250), goat anti-guinea pig (1:300, both 
Jackson ImmunoResearch). Cell nuclei were visualized with DAPI dissolved in H20 
(0.01µg/mL, Sigma-Aldrich). After washing in PBS sections were mounted on Super 
Frost microscopic slides, dried and covered with Aqua-Poly/Mount (Polysciences). All 
stainings were scanned by confocal microscopy (TCS SP5-II, Leica). Illustration was 
done using Imaris 7.5.1 (www.bitplane.com). 
 
Immunohistochemistry on paraffin embedded human brain sections 
Brain slices of 1-3µm thickness from formalin-fixed and paraffin-embedded tissue 
blocks were deparaffinized. Endogenous peroxidases were blocked with 3% H2O2 in 
PBS for 20min followed by epitope blocking with 0.02% casein in PBS for 15min. 
Immunoreaction was performed by incubation with ctEPOR-AB (1:500, Synaptic 
Systems) over night at RT, followed by addition of the secondary biotinylated donkey 
anti-rabbit AB (1:500; Amersham Biosciences Freiburg, Germany) and an extravidin-
peroxidase enzyme complex (1:1000; Sigma-Aldrich), each for 1h at RT. The AB 
reaction was visualized with the chromogen AEC: 4mL 4% 3-amino-9-ethylcarbazole 
(Sigma-Aldrich) in N,N-dimethylformamide (Merck) were dissolved in 56mL 0.1M 
sodium-acetate buffer adjusted to pH5.2 with acetic acid and 1% H2O2. The brain 









Generation of EPOR-AB 
The aim of this work was to generate specific and sensitive EPOR-AB and to 
investigate EPOR expression in the central nervous system (CNS). Therefore, 
polyclonal rabbit EPOR-AB and monoclonal mouse EPOR-AB were produced and 
tested. After extensive characterization of a whole panel of AB (data not shown), 2 


















purposes: (I) The polyclonal rabbit EPOR-AB SA7378, directed against the C-
terminus (here always referred to as ctEPOR-AB) and (II) the monoclonal mouse 
EPOR-AB 45A3, directed against the N-terminus (here referred to as ntEPOR-AB). 
The present study is mainly built on ctEPOR-AB because of its high specificity and 
broad spectrum of applications in human and mouse.  
 
Functional EPOR validation in the test systems 
As prerequisite of testing EPOR-AB in the cell lines used here, we functionally 
validated their EPOR expression. In the EPO-dependent megakaryoblastic 
leukaemia cell line UT-7, incubation with different concentrations of rhEPO led to 
STAT-5 phosphorylation (Fig.1A). Also, in the erythroleukaemia cell line OCIM-1, 
incubation with rhEPO induced STAT-5 phosphorylation (Fig.1B). UT-7 cells only 
proliferated and survived in the presence of rhEPO in the medium (Fig.1C-D). In the 
mouse microglia cell line EOC-20, stably transduced with N-terminally HA-tagged 
human EPOR, rhEPO administration activated MAPK phosphorylation in a 
concentration-dependent manner (Fig.1E). We also confirmed EPOR mRNA 
expression in all of these cell lines by qPCR (normalized to GAPDH as housekeeping 
gene – data not shown). 
 
Detection of EPOR/EpoR by Western blotting 
To confirm reliable detection of EPOR by Western blotting, we transfected HEK293 
FT cells with different EPOR expression vectors. The polyclonal rabbit ctEPOR-AB 
detected full-length human EPOR and its degradation product specifically while the 
C-terminally truncated mutant of EPOR was not detected by this AB (Figs.1F-G). 
Immunoblots of lysates from transduced EOC-20 cells (N-terminally HA-tagged 
human EPOR) and respective controls showed specific detection of full-length human 
EPOR by ctEPOR-AB (Fig.1H). This was validated with an HA immunoblot of the 
same lysates (Fig.1I). In protein lysates from UT-7 and OCIM-1 cells, ctEPOR-AB 
detected bands of the same molecular weight (Fig.1J). As shown in Fig.1F and J, in 
UT-7 cells and HEK293 FT cells (only when transfected with the full length human 
EPOR) a specific degradation product was additionally detected at ~40kDa by the 
ctEPOR-AB. This degradation product of EPOR has been described earlier (11). 


















with ctEPOR-AB (Fig.1K). EPOR was further recognized by ctEPOR-AB in human 
placenta and fetal brain extracts (Fig.1L). In addition to human EPOR, ctEPOR-AB 
detected murine EpoR in transfected HEK293 FT cells, mouse fetal liver and lysates 
from cultured primary mouse oligodendrocytes (Fig.1M). To validate the specificity of 
murine EpoR detection, EpoR was knocked out in primary astrocytes derived from 
EpoR-fl/fl mice. In fact, ctEPOR-AB recognized a doublet of bands (EPOR with or 
without N-glycosylation, resulting in a difference of ~3kDa) with a molecular weight of 
around 65kDa (Fig.1N, control transduction). Shown is a clear reduction upon 
expression of Cre-recombinase. The residual expression of the protein is likely due to 
a slow turnover of EpoR, slow kinetics of Cre-recombination of the floxed EpoR 
allele, or incomplete infection of the lentivirus. In any case, Cre-dependent reduction 
of the signal led us to conclude that ctEPOR-AB specifically detects EpoR. Together, 
these results indicate specific EPOR/EpoR detection with ctEPOR-AB in human and 
murine cell and tissue extracts. 
 
EPOR protein identification 
To test whether the specific band detected in Western blots is indeed EPOR, we 
performed immunoprecipitations (IP) from UT-7 lysates and subsequent mass 
spectrometric protein identification. We used covalently immobilized ctEPOR-AB in 
combination with non-reducing elution conditions to minimize the masking effect of 
excess antibody heavy chains, which have an apparent electrophoretic mobility 
similar to the EPOR. After IP with ctEPOR-AB, eluted proteins from ctEPOR-AB 
protein-G sepharose beads and respective control beads were separated by SDS-
PAGE and visualized by colloidal Coomassie staining or immunoblotting. The overlay 
of the 2 gel images (Fig.2A) was used to identify the region of the Coomassie-stained 
gel potentially containing the EPOR protein. Identical gel regions from ctEPOR-AB IP 
and the control IP were excised and subjected to tryptic digestion followed by liquid 
chromatography coupled to mass spectrometry (LC-MS). Against a common 
background mainly consisting of chaperone proteins, human EPOR protein was 
detected in eluates from ctEPOR-AB beads, but not from control beads. The 
identification of 11 EPOR derived peptides with high mass accuracy at both precursor 
and fragment ion level resulted in sequence coverage of 22.6% (Fig.2B-C), basically 


















our results show that ctEPOR-AB indeed binds specifically to full-length EPOR. Also, 
in reducing conditions we could effectively elute EPOR after IP (Fig.2D). Noteworthy, 
we detected the EPOR protein in Western blots between 59-68 kDa, depending on 
the gel system and protein molecular weight marker used (see Fig.1, 2A and D and 
material and methods). 
 
EPOR/EpoR detection by immunocytochemistry 
To validate the specificity of ctEPOR-AB on formaldehyde fixed cells, we stained the 
same antigen with AB directed against different epitopes (38). In EOC-20 cells 
transduced with an N-terminally HA-tagged human EPOR, anti-HA and ctEPOR-AB 
double-staining showed almost complete co-localization with most of the signal 
located intracellularly (Fig.3A). Control EOC-20 cells were negative (Fig.3A). In UT-7 
cells, ctEPOR-AB revealed a similar staining pattern (Fig.3B). EPOR staining was co-
localized with Golgi staining, indicating detection of a membrane protein (Fig.3C). In 
addition, ntEPOR-AB and ctEPOR-AB double-stained EPOR in UT-7 cells (Fig.3D). 
In OCIM-1 cells, ctEPOR-AB also yielded intracellular staining, even though less 
pronounced compared to UT-7 cells (Fig.3E). Using ctEPOR-AB, we also detected 
EPOR in human IPS cells (Fig.3F). Moreover, ctEPOR-AB specifically stained 
HEK293 FT cells transfected with full-length murine EpoR (Fig.3G). When tested on 
cultured primary murine brain cells, ctEPOR-AB stained oligodendrocyte precursor 
cells (Fig.3H), oligodendrocytes (Fig.3I) and microglia (Fig.3J). These results indicate 
specific staining of human and mouse EPOR/EpoR by the ctEPOR-AB in cell lines 
and primary cells. 
 
EpoR detection in the brain of healthy mice 
Using ctEPOR-AB on frozen brain sections of healthy young mice, we found EpoR 
expression mainly in a subpopulation of cells of the oligodendrocyte lineage (Fig.4A). 
To get better insight at which stages cells of the oligodendrocyte lineage express 
EpoR, we labelled oligodendrocyte precursor cells by tamoxifen injections in NG2-
CreERT2 mice (28). At 72h after the second tamoxifen injection, we identified 
precursors double-stained for GFP and ctEPOR-AB (GFP+/EPOR+), as well as 
GFP+/EPOR+ cells with clear morphology (processes with parallel myelin bundles) of 
already differentiated oligodendrocytes (Fig.4B-B’’). Moreover, GFAP+/ EPOR+ cells 


















subventricular zone (data not shown). These results indicate EPOR expression in 
differentiating oligodendrocytes and stem cells in the adult neurogenic niches of 
healthy young mice. 
 
EPOR/EpoR detection in the injured CNS of mice 
Next, we stereotactically injected EPOR-transduced EOC-20 cells or medium only 
(‘stab wound’ analogue) in the motor cortex of adult mice (Fig.4D). This experiment 
served 2 purposes: [1] to recover defined cells that carry human EPOR in brain 
sections; [2] to confirm injury-induced endogenous EpoR expression, since in earlier 
work, we had proposed upregulation of EPOR upon injury (6). At 24h after injection of 
medium only (‘stab wound’), we saw cells with strong ctEPOR-AB signal in close 
proximity to the injection site (Fig.4E). Many of these cells were GFAP+/EPOR+ 
(Fig.4F). On the contralateral site, no GFAP+/EPOR+ cells were seen (Fig.4G). In the 
motor cortex of mice injected with transduced EOC-20 cells (murine microglia cell 
line), double-labelling with HA-AB and ctEPOR-AB confirmed specific recovery of 
these cells in frozen sections of paraformaldehyde-perfused mice. Also in this 
condition, endogenous cells with high EpoR expression were observed in close 
proximity of the injection site (Fig.4H-H’’). These results confirm the pronounced 
upregulation of EpoR in cells reacting to injury, provoked here by an experimental 
stab wound. 
 
Upregulation of EPOR in the hippocampal formation of a patient suffering from 
temporo-mesial complex-focal epilepsy 
Formalin-fixed, paraffin-embedded tissue from a patient, who underwent selective 
unilateral hippocampectomy, was used for immunohistochemical detection of EPOR 
upregulation under these conditions (Fig.5A). The patient had been suffering from 
pharmaco-resistant complex-focal seizures of temporo-mesial origin for more than 10 
years. Neuropathological analysis of the surgery material revealed hippocampal 
sclerosis stage Wyler III. EPOR was upregulated in several but not all remaining 
neurons of CA1 (Fig.5B), of CA4 (Fig.5C) and of the dentate gyrus (Fig.5D), as well 
as in oligodendrocytes and endothelial cells of capillaries in the adjacent white matter 
(Fig.5E). Without primary AB, no staining could be detected (Fig.5F). This suggests 





















In the present work, we took the challenge requested for a long time by the scientific 
community (14, 17-18) to generate a specific AB for valid detection of EPOR in 
human and murine cells and tissues, with particular focus on the brain. We present 
here a highly specific polyclonal rabbit AB directed against the intracellular C-
terminus of the human EPOR. This AB, referred to as ctEPOR-AB, specifically 
recognizes EPOR, as proven by mass spectrometry, and has a broad range of 
documented applications in both human and murine cells and tissues, ranging from 
Western blotting, flow cytometry, and immunoprecipitation to immunocytochemistry 
and immunohistochemistry on frozen as well as paraffin-embedded sections. 
Importantly, by employing this AB, we were able to confirm expression of EPOR in 
brain cells and its upregulation upon injury (39). Our comprehensive in vitro and in 
vivo data clearly reject earlier claims, solely based on in vitro studies, that EPOR 
expression and EPO function outside the hematopoietic system does not exist (15).  
 
The great need for specific EPOR-AB in the field is also reflected by a very recent 
study of Drorit Neumann and colleagues (37). This group of authors published 
specific mouse and rat monoclonal EPOR-AB that detect EPOR expression in human 
cancer cells and tissues (37). Complementary to this approach and with particular 
focus on the brain, we have developed a highly specific and sensitive polyclonal 
rabbit AB, ctEPOR-AB, suitable for applications not only in human but also in murine 
material. Since the polyclonal nature of this AB has limitations, not only due to the 
restricted life time of a rabbit, we are currently working on further exploitation of the 
herewith acquired knowledge. Preliminary results of epitope mapping with this 
polyclonal ctEPOR-AB revealed only few strongly recognized epitopes. These 
epitopes are presently used for generating specific mouse monoclonal AB. They will 
be tested alone or in the form of potentially more sensitive ‘cocktails’, with collective 
properties similar to the here reported ctEPOR-AB. 
 
With the examples of EPOR expression in the brain shown here, we confirmed earlier 
work of ourselves and others which needed in the past additional methods for 


















previous EPOR-AB. For instance, GFAP positive stem cells in the adult neurogenic 
niches showed EpoR immunoreactivity here, which is in line with reports 
demonstrating distinct effects of EPO on adult neural stem cells (40-41). Also, studies 
identifying EPO as inducer of oligodendrocyte precursor cell differentiation (42-43) 
are now further supported by the detection of specific EPOR binding sites in culture 
and brain sections. Importantly, the role of the EPO/EPOR system in response to 
brain injury (5-6) is confirmed with our stab wound approach.  
 
To conclude, based on the here reported novel tool, it will now be possible to 
investigate the role of EPOR in the intact and injured human and murine brain in 
more detail. This, in turn, will facilitate the development of EPO for therapeutic use 
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FIGURE LEGENDS  
 
Figure 1: Functional EPOR validation and EPOR/EpoR detection using ctEPOR-
AB in Western blots. (A) Incubation of EPO-dependent UT-7 cells (after 12h of EPO 
deprivation) for 15min with increasing EPO concentrations induced STAT5 
phosphorylation. (B) Incubation of OCIM-1 cells for 15min with increasing EPO 
concentrations induced STAT5 phosphorylation. (C) Cell counts of EPO-dependent 
UT-7 cultures 72h after seeding in presence and absence of EPO (n=6, mean±SEM; 
p<0.0001). (D) Cell death in EPO-dependent UT-7 cultures 72h after seeding in 
presence and absence of EPO (n=5, mean±SEM; p<0.03). (E) Incubation of EOC-20 
cells transduced with HA-tagged human EPOR for 10min with increasing EPO 
concentrations induced MAPK phosphorylation. (F) EPOR Western blot using 
ctEPOR-AB on transfected HEK293 FT cell lysates (truncated HA-EPOR: human 
EPOR lacking the C-terminus, HA-tag at the N-terminus; control vector: anchored 
human EPOR without N-terminus and C-terminus). (G) HA Western blot of the same 
transfected HEK293 FT cell lysates used in (F). (H) EPOR Western blot using 
ctEPOR-AB on EOC-20 cell lysates transduced with N-terminally HA-tagged human 
EPOR and respective controls. (I) HA Western blot of the same EOC-20 cell lysates 
used in (H). (J) EPOR Western blot using ctEPOR-AB on UT-7 and OCIM-1 cell 
lysates. (K) Flow cytometry of fixed UT-7 cells stained with ctEPOR-AB and 
Alexa488 donkey anti-rabbit secondary AB; as control secondary AB only. (L) EPOR 
detection in human placenta and human fetal brain using ctEPOR-AB. (M) Detection 
of murine EpoR in transfected HEK293 FT cells overexpressing murine EpoR, mouse 
fetal liver and mouse primary oligodendrocytes using ctEPOR-AB. (N) Lentivirus-
mediated conditional EpoR knockout in primary EpoR-fl/fl mouse astrocytes; anti-
alpha tubulin as stably expressed comparator. 
 
Figure 2: EPOR immunoprecipitation using ctEPOR-AB and protein 
identification by mass spectrometry. (A) Colloidal Coomassie staining and 
immunoblot of the same EPOR immunoprecipitation using ctEPOR-AB from UT-7 
protein lysates. The overlay was used to determine the region to be excised from the 
Coomassie gel for subsequent mass spectrometric protein identification (area 


















(B) Amino acid sequence of EPOR (UniProtKB/Swiss-Prot P19235). Peptides 
identified by mass spectrometry are indicated in red. Note that large parts of the 
EPOR precursor sequence (indicated in italics) cannot be covered in a standard 
proteomic experiment with tryptic cleavage as they are either modified (amino acids 
1-34, signal peptide; 57-89, N-glycosylation site), attached to the transmembrane 
domain (224-275) or too large (> 5kDa) to reveal useful information by mass 
spectrometric sequencing (379-453, 454-508). (C) Table with details on peptide 
identification. Columns show from left to right: numbering of tryptic peptides; 
numbering of amino acids according to the sequence in B; peptide sequence (c, 
carboxamidomethyl-Cys); observed and calculated mass of the singly protonated 
peptide; peptide mass deviation in ppm; PLGS score; number of b-y fragment ions; 
root mean square fragment mass deviation in ppm. (D) Immunoblot of EPOR 
immunoprecipitation using ctEPOR-AB from UT-7 lysates. In contrast to the 
immunoprecipitation used for mass spectrometry, EPOR was eluted from the beads 
in reducing conditions (Laemmli buffer with β-mercaptoethanol, abbreviations: 
FT=flow through, IP=immunoprecipitation, Ig HC=immunoglobulin heavy chains, Ig 
LC=immunoglobulin light chains). The prominent band at around 40kDa in both IP 
conditions has to be an immunoglobulin fragment eluted from the beads in the 
reducing condition only, since it was not eluted without β-mercaptoethanol (see 
subpanel 2A immunoblot). 
 
Figure 3: Detection of EPOR by immunocytochemistry: (A) EPOR detection 
using ctEPOR-AB and monoclonal HA-AB on transduced (N-terminally HA-tagged 
human EPOR, upper row) and control (lower row) EOC-20 cells. (B) EPOR staining 
with ctEPOR-AB on EPO-dependent UT-7 cells. (C) Double-Immunostaining of UT-7 
cells with anti-GM130 AB as marker for the Golgi apparatus and ctEPOR-AB. (D) 
EPOR double staining of UT-7 cells with ntEPOR AB and ctEPOR-AB. (E) EPOR 
staining with ctEPOR-AB on OCIM-1 cells. (F) Distinct EPOR staining in human Oct-
4+ IPS cells using ctEPOR-AB. (G) EpoR staining with ctEPOR-AB of HEK 293 FT 
cells transfected with full-length murine EpoR. Neighbouring non-transfected cells 
show no immunofluorescence. (H) EpoR and NG2 double-staining with ctEPOR-AB 


















of primary mouse oligodendrocytes with ctEPOR-AB. (J) Detection of EpoR in 
primary mouse microglia using ctEPOR-AB and lectin as counterstain. 
 
Figure 4: EPOR detection using ctEPOR-AB in healthy and injured mouse brain 
by immunohistochemistry: (A) EpoR staining in a subpopulation of CC-1 positive 
mature oligodendrocytes in the neocortex of a 5 week-old healthy mouse. (B, B’, B’’) 
EpoR staining in the hippocampus of a 5 week-old NG2-CreERT2:R26-td-tomato-
mEGFP mouse. Some oligodendrocyte precursor cells (arrow head) and newly 
differentiated oligodendrocytes (arrow) express EpoR. Both cell types are 
endogenously labelled with membrane-tagged EGFP. (C) EpoR staining of GFAP+ 
cellular processes in the dentate gyrus of a 5 week-old mouse (arrow heads). (D) 
Overview of the injection site in the motor cortex of an 8 week-old mouse injected 
with medium only (‘stab wound’ analogue). The section was stained for neuronal 
nuclei with NeuN and for EpoR with ctEPOR-AB. (E) Close-up of the white-rectangle 
region in (D) shows reactive cells with up-regulated EpoR expression. (F) Many of 
the cells at the injection site with up-regulated EpoR expression are GFAP+ (arrow 
heads). (G) Contralateral to the injection site, GFAP+ cells show no EpoR expression 
at 24h after lesion. (H, H’, H’’) Shown is EPOR and HA double-labelling of injected 
EOC-20 microglial cells transduced with an HA-tagged human EPOR. In addition, 
HA-negative cells at the injection site show strong EpoR expression (arrow heads).   
 
Figure 5: EPOR upregulation in neurons and oligodendrocytes of the 
hippocampal formation of a patient suffering from temporo-mesial complex-
focal epilepsy as demonstrated by immunohistochemistry using ctEPOR-AB. 
(A) Overview of the surgical sample stained with ctEPOR-AB. (B) Upregulation of 
EPOR, visualized by brown colour of the AEC-chromogen, in some (arrows) but not 
all (arrow heads) neurons of the CA1 region. (C) EPOR positive neurons in the CA4 
region (arrows). (D) Dentate gyrus neurons (arrows) expressing EPOR. (E) EPOR 
positive oligodendrocytes (arrows) as well as endothelial cells of capillaries (arrow 
heads) in the adjacent white matter. (F) No staining was observed when omitting the 
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